Relevant bibliographies by topics / Pharmaceutical delivery technologies

Academic literature on the topic 'Pharmaceutical delivery technologies'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical delivery technologies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical delivery technologies"

1

Marcato, Priscyla D., and Nelson Durán. "New Aspects of Nanopharmaceutical Delivery Systems." Journal of Nanoscience and Nanotechnology 8, no. 5 (May 1, 2008): 2216–29. http://dx.doi.org/10.1166/jnn.2008.274.

Full text
Abstract:
Nanobiotechnology, involving biological systems manufactured at the molecular level, is a multidisciplinary field that has fostered the development of nanoscaled pharmaceutical delivery devices. Micelles, liposomes, solid lipid nanoparticles, polymeric nanoparticles, functionalized nanoparticles, nanocrystals, cyclodextrins, dendrimers, nanotubes and metallic nanoparticles have been used as strategies to deliver conventional pharmaceuticals or substances such as peptides, recombinant proteins, vaccines and nucleotides. Nanoparticles and other colloidal pharmaceutical delivery systems modify many physicochemical properties, thus resulting in changes in the body distribution and other pharmacological processes. These changes can lead to pharmaceutical delivery at specific sites and reduce side effects. Therefore, nanoparticles can improve the therapeutic efficiency, being excellent carriers for biological molecules, including enzymes, recombinant proteins and nucleic acid. This review discusses different pharmaceutical carrier systems, and their potential and limitations in the field of pharmaceutical technology. Products with these technologies which have been approved by the FDA in different clinical phases and which are on the market will be also discussed.
APA, Harvard, Vancouver, ISO, and other styles
2

Sullivan, Vincent J., John A. Mikszta, Philippe Laurent, Juan Huang, and Brandi Ford. "Noninvasive delivery technologies: respiratory delivery of vaccines." Expert Opinion on Drug Delivery 3, no. 1 (December 22, 2005): 87–95. http://dx.doi.org/10.1517/17425247.3.1.87.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rossi, Alessandra. "Innovative Technologies for Oral Drug Delivery." Current Drug Delivery 10, no. 1 (February 1, 2013): 4–8. http://dx.doi.org/10.2174/1567201811310010003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jain, Deepika, Vikas Jain, and Ranjit Singh. "Novel antigen delivery technologies: a review." Drug Delivery and Translational Research 1, no. 2 (January 25, 2011): 103–12. http://dx.doi.org/10.1007/s13346-011-0014-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Phillips, Brett E., and Nick Giannoukakis. "Drug delivery technologies for autoimmune disease." Expert Opinion on Drug Delivery 7, no. 11 (October 20, 2010): 1279–89. http://dx.doi.org/10.1517/17425247.2010.527329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sant, Shilpa, Sarah L. Tao, Omar Z. Fisher, Qiaobing Xu, Nicholas A. Peppas, and Ali Khademhosseini. "Microfabrication technologies for oral drug delivery." Advanced Drug Delivery Reviews 64, no. 6 (May 2012): 496–507. http://dx.doi.org/10.1016/j.addr.2011.11.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Benson, Heather A. E., Jeffrey E. Grice, Yousuf Mohammed, Sarika Namjoshi, and Michael S. Roberts. "Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies." Current Drug Delivery 16, no. 5 (May 29, 2019): 444–60. http://dx.doi.org/10.2174/1567201816666190201143457.

Full text
Abstract:
This overview on skin delivery considers the evolution of the principles of percutaneous absorption and skin products from ancient times to today. Over the ages, it has been recognised that products may be applied to the skin for either local or systemic effects. As our understanding of the anatomy and physiology of the skin has improved, this has facilitated the development of technologies to effectively and quantitatively deliver solutes across this barrier to specific target sites in the skin and beyond. We focus on these technologies and their role in skin delivery today and in the future.
APA, Harvard, Vancouver, ISO, and other styles
8

Simerska, Pavla, Peter Moyle, Colleen Olive, and Istvan Toth. "Oral Vaccine Delivery – New Strategies and Technologies." Current Drug Delivery 6, no. 4 (August 1, 2009): 347–58. http://dx.doi.org/10.2174/156720109789000537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Obata, Yoko, Tomoya Nishino, and Shigeru Kohno. "Technologies of Drug Delivery System for Nephrology." Drug Delivery System 27, no. 4 (2012): 257–66. http://dx.doi.org/10.2745/dds.27.257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mohammed, Abdullah, Amr Elshaer, Pooya Sareh, Mahmoud Elsayed, and Hany Hassanin. "Additive Manufacturing Technologies for Drug Delivery Applications." International Journal of Pharmaceutics 580 (April 2020): 119245. http://dx.doi.org/10.1016/j.ijpharm.2020.119245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical delivery technologies"

1

Bassett, Pamela. Drug delivery systems: Technologies, trends and market opportunities. 4th ed. Southborough, MA: International Business Communications, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yeo, Yoon. Nanoparticulate drug delivery systems: Strategies, technologies, and applications. Hoboken, New Jersey: Wiley, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bassett, Pamela. Delivery systems for cosmetic ingred: Technologies, trends, and market opportunities. Southborough, MA: International Business Communications, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

(Firm), Knovel, ed. Drug-device combination products: Delivery technologies and applications. Boca Raton: CRC Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Transdermal and intradermal delivery of therapeutic agents: Application of physical technologies. Boca Raton, FL: CRC Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

G, Popovich Nicholas, and Ansel Howard C. 1933-, eds. Pharmaceutical dosage forms and drug delivery systems. 5th ed. Philadelphia: Lea & Febiger, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Max, Donbrow, ed. Microcapsules and nanoparticles in medicine and pharmacy. Boca Raton: CRC Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

McNally, Eugene, and Jayne E. Hastedt. Biopharmaceutical Formulation and Delivery Technologies, Third Edition. Taylor & Francis Group, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Castro, E. A., and A. K. Haghi. Nanotechnology in Drug Delivery: Strategies, Technologies and Applications. Nova Science Publishers, Incorporated, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Darryl, León, and Markel Scott, eds. In silico technologies in drug target identification and validation. Boca Raton: CRC Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical delivery technologies"

1

Chevalier, M. T., J. S. Gonzalez, and V. A. Alvarez. "Polymers for Peptide/Protein Drug Delivery." In Handbook of Polymers for Pharmaceutical Technologies, 433–56. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041375.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mody, Nishi, Udita Agrawal, Rajeev Sharma, and S. P. Vyas. "Structured Biodegradable Polymers for Drug Delivery." In Handbook of Polymers for Pharmaceutical Technologies, 243–74. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041450.ch8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pina, M. E., P. Coimbra, P. Ferreira, P. Alves, A. I. Figueiredo, and M. H. Gil. "Polymeric Materials in Ocular Drug Delivery Systems." In Handbook of Polymers for Pharmaceutical Technologies, 439–58. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041412.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Censi, Roberta, Alessandra Dubbini, and Piera Di Martino. "In-SituGelling Thermosensitive Hydrogels for Protein Delivery Applications." In Handbook of Polymers for Pharmaceutical Technologies, 95–120. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041412.ch4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Girotra, Priti, and Shailendra Kumar Singh. "Chitosan: An Emanating Polymeric Carrier for Drug Delivery." In Handbook of Polymers for Pharmaceutical Technologies, 33–60. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041450.ch2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Patil, Payal H., Chandrakantsing V. Pardeshi, Hitendra S. Mahajan, and Sanjay J. Surana. "Hemicellulose-Based Delivery Systems: Focus on Pharmaceutical and Biomedical Applications." In Clean Energy Production Technologies, 467–507. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-3682-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

El-Sherbiny, Ibrahim M., Nancy M. El-Baz, and Amr H. Mohamed. "Biodegradable and Biocompatible Polymers-Based Drug Delivery Systems for Cancer Therapy." In Handbook of Polymers for Pharmaceutical Technologies, 373–406. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041559.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

de Lima, Gabriel Goetten, Diwakar Kanwar, Derek Macken, Luke Geever, Declan M. Devine, and Michael J. D. Nugent. "Smart Hydrogels: Therapeutic Advancements in Hydrogel Technology for Smart Drug Delivery Applications." In Handbook of Polymers for Pharmaceutical Technologies, 1–16. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041559.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Armentano, Ilaria, Loredana Latterini, Nicoletta Rescignano, Luigi Tarpani, Elena Fortunati, and José Maria Kenny. "Engineering Biodegradable Polymers to Control Their Degradation and Optimize Their Use as Delivery and Theranostic Systems." In Handbook of Polymers for Pharmaceutical Technologies, 557–76. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119041450.ch17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kontogiannatos, Dimitrios, Anna Kolliopoulou, and Luc Swevers. "The 'Trojan horse' approach for successful RNA interference in insects." In RNAi for plant improvement and protection, 25–39. Wallingford: CABI, 2021. http://dx.doi.org/10.1079/9781789248890.0004a.

Full text
Abstract:
Abstract Since the discovery of RNA interference in 1998 as a potent molecular tool for the selective downregulation of gene expression in almost all eukaryotes, increasing research is being performed in order to discover applications that are useful for the pharmaceutical and chemical industry. The ease of use of double-stranded RNA for targeted in vivo gene silencing in animal cells and tissues gave birth to a massive interest from industry in order to discover biotechnological applications for human health and plant protection. For insects, RNAi became the 'Holy Grail' of pesticide manufacturing, because this technology is a promising species-specific environmentally friendly approach to killing natural enemies of cultured plants and farmed animals. The general idea to use RNAi as a pest-control agent originated with the realization that dsRNAs that target developmentally or physiologically important insect genes can cause lethal phenotypes as a result of the specific gene downregulation. Most importantly to achieve this, dsRNA is not required to be constitutively expressed via a transgene in the targeted insect but it can be administrated orally after direct spraying on the infested plants. Similarly, dsRNAs can be administered to pests after constitutive expression as a hairpin in plants or bacteria via stable transgenesis. Ideally, this technology could have already been applied in integrated pest management (IPM) if improvements were not essential in order to achieve higher insecticidal effects. There are many limitations that decrease RNAi efficiency in insects, which arise from the biochemical nature of the insect gut as well as from deficiencies in the RNAi core machinery, a common phenomenon mostly observed in lepidopteran species. To overcome these obstacles, new technologies should be assessed to ascertain that the dsRNA will be transferred intact, stable and in high amounts to the targeted insect cells. In this chapter we will review a wide range of recent discoveries that address the delivery issues of dsRNAs in insect cells, with a focus on the most prominent and efficient technologies. We will also review the upcoming and novel use of viral molecular components for the successful and efficient delivery of dsRNA to the insect cell.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical delivery technologies"

1

Sandhu, Jaspal S., Aman Bhandari, Mahad Ibrahim, and P. Balakrishnan. "Appropriate Design of Medical Technologies for Emerging Regions: The Case of Aurolab." In ASME 2005 International Mechanical Engineering Congress and Exposition. ASMEDC, 2005. http://dx.doi.org/10.1115/imece2005-81291.

Full text
Abstract:
Healthcare delivery in emerging regions presents a unique set of challenges and is characterized largely by poor infrastructure. Though there is significant variation from country to country - and even within countries - in emerging regions, common themes emerge, such as overreliance on direct payment schemes, unreliable supply chains, and intermittent power in rural settings. These themes in turn impose particular design requirements on manufacturers of medical devices and pharmaceuticals; this paper focuses on these design requirements. We illustrate the importance of designing specifically for the developing context, using the example of Aurolab, a non-profit medical manufacturer located in Tamil Nadu, India. Started in 1992, Aurolab began operations with the manufacture of intraocular lenses (IOL), implantable polymer lenses for cataract surgery, becoming the first to produce this technology in India. Today Aurolab produces a variety of medical devices and ophthalmic pharmaceuticals, and deliver their products to 120 countries worldwide. Aurolab’s products illustrate many of the key design requirements for healthcare delivery in India and in other emerging contexts.
APA, Harvard, Vancouver, ISO, and other styles
2

Lu, Li, Rebecca M. Irwin, Jeffrey W. Schertzer, and Paul R. Chiarot. "Particulate and Emulsion Sorting Using Microfluidics." In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-38298.

Full text
Abstract:
We report on a microfluidic device capable of sorting nanoscale particulates and water-in-oil emulsions at high-throughput. The device is passive, relying solely on hydrodynamic forces and the emulsion mass to achieve separation. We use the microfluidic device to deliver surfactants and lipids to the emulsion surface. This is achieved by immersing the emulsions in a fluid stream with a high concentration of the nano-particulates. The particulates assemble on the surface of the emulsions as they are transported along the stream. The emulsions are then transferred (i.e. separated) into a second fluid stream that is devoid of surrounding material. The performance of the device is evaluated for a range of flow rates, nano-particulate concentrations, and emulsion sizes. We report separation efficiencies that exceed current technologies over a wide range of flow rates. The microfluidic device can be used to produce delivery vehicles for pharmaceuticals and models for membrane biology studies.
APA, Harvard, Vancouver, ISO, and other styles
3

Neves, Marcos A., Isao Kobayashi, and Mitsutoshi Nakajima. "Scaling-Up Microchannel Emulsification Foreseeing Novel Bioactives Delivery Systems." In ASME 2013 11th International Conference on Nanochannels, Microchannels, and Minichannels. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/icnmm2013-73116.

Full text
Abstract:
In the recent years, emulsification technologies that generate droplets individually have attracted a great deal attention in various fields, e.g., for chemicals, cosmetics, foods, and pharmaceuticals. Such drop-by-drop emulsification technologies include membrane emulsification using microporous membranes and microchannel (MC) emulsification, among others. The authors developed MC emulsification chips, consisting of parallel microgrooves or compactly arranged straight through-holes. Using this MC emulsification technique, the authors have evaluated the formulation a two-phase system consisting of size-controlled O/W emulsions loaded with bioactive molecules, such as β-carotene or γ-oryzanol, PUFAs or polyphenols. The MC emulsification process enabled the production of β-carotene-loaded O/W emulsions with average droplet size (dav) of 27.6 μm and coefficient of variation (CV) of 2.3% and γ-oryzanol-loaded droplets with dav of 28.8 μm and CV of 3.8%. The highly monodisperse O/W emulsions were physically stable during up 4 months storage in darkness at 5 °C. In addition, we investigated the formation characteristics of O/W emulsion droplets in the presence of electrolyte by MC emulsification using differently charged surfactants. Droplet formation was conducted by pressurizing a dispersed phase (refined soybean oil) through the MC silicon chip into a continuous phase containing 1.0 wt% of sodium dodecyl sulfate (SDS) or polyoxyethylene (20) sorbitan monolaurate (Tween 20), and an electrolyte (NaCl) (0–1.0 mol/L). Monodisperse O/W emulsions with an dav of 26 μm and a CV below 5% were produced when the NaCl concentration was lower than a threshold level that is 0.3 mol/L for SDS and 0.5 mol/L for Tween 20. The authors also developed a large MC emulsification device including a newly designed asymmetric MC array chip to realize the mass production of uniformly sized droplets on a liter per hour scale, so that satisfying the minimum droplet productivity needed for industrial-scale production. The large MC emulsification device has a potential droplet productivity exceeding several tons per year, which could satisfy a minimum industrial-scale production of monodisperse microdispersions containing emulsion droplets, microparticles, and microcapsules loaded with bioactive compounds. Such systems have as continuously increasing potential application in the formulation of functional foods, providing a good opportunity to improve the solubility of bioactive compounds, so that increasing their bioavailability.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical delivery technologies' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography